U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s ...

U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...

Capricor Therapeutics (NASDAQ:CAPR) shares dropped after the U.S. FDA inspected its San Diego manufacturing facility for the ...

Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...

Benzinga's options scanner spotted 10 options trades for Capricor Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 20% bullish and 70% bearish. Among ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

Capricor Therapeutics (NASDAQ:CAPR) received the Orphan Drug designation from the U.S. FDA for its lead cell therapy candidate, Deramiocel, to treat becker muscular dystrophy. With its orphan drug ...

“This inspection outcome is a major regulatory milestone, particularly in a field where standards are exceptionally high,” said Linda Marbán, Ph.D., Capricor’s Chief Executive Officer.

"This inspection outcome is a major regulatory milestone, particularly in a field where standards are exceptionally high,” said Linda Marbán, Ph.D., Capricor's Chief Executive Officer. "It reflects ...